ACAD vs CORT
ACADIA Pharmaceuticals Inc. vs Corcept Therapeutics Incorporated — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
CORT
Corcept Therapeutics Incorporated
56
Watch
| Metric | ACAD | CORT |
|---|
| AI Score |
69
|
56
|
| Price |
$29.41
|
$111.83
|
| P/E Ratio |
13.07×
|
215.12×
|
| ROE |
31.9%
|
15.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
98.3%
|
| Debt / Equity |
0.06×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
61.4
|
| Beta |
0.845
|
0.455
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus CORT.
ACAD leads by 13 points.
ACAD scores 69/100 (Buy) versus CORT at 56/100 (Watch).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
CORT Committee View
67% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 223.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- P/E of 223.5 is expensive by classic value standards — Value
- Price-to-book of 11.4x prices in significant intangible value — Value
- EPS declining -62.5% YoY despite any revenue growth — Growth